Ropeginterferon alfa-2b was moved to preferred status for patients with high- and low-risk polycythemia vera in a recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice ...
The US Food & Drug Administration (FDA) approved BESREMi® (active pharmaceutical ingredient Ropeginterferon alfa-2b), confirming the efficacy and safety for treatment of Polycythaemia Vera, a rare ...
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results